Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 2 completed trials

    Completion Rate
    100%(2/2)
    Active Trials
    0(0%)
    Results Posted
    0%(0 trials)

    Phase Distribution

    Phase 2/3
    1
    50%
    Not Applicable
    1
    50%

    Phase Distribution

    0

    Early Stage

    1

    Mid Stage

    0

    Late Stage

    Phase Distribution2 total trials
    Phase 2/3Combined phases
    1(50.0%)
    N/ANon-phased studies
    1(50.0%)

    Highest Phase Reached

    Phase 2/3

    Trial Status & Enrollment

    Completion Rate

    100.0%

    2 of 2 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    2

    all time

    Status Distribution
    Completed(2)

    Detailed Status

    Completed2

    Development Timeline

    Analytics

    Development Status

    Total Trials
    2
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 2/3

    Trials by Phase

    Phase 2/31 (50.0%)
    N/A1 (50.0%)

    Trials by Status

    completed2100%

    Recent Activity

    0 active trials
    Showing 2 of 2
    completednot_applicable

    Mode of Action (MoA) Study of TOTUM-63 in Individuals at Increased Cardio-metabolic Risk

    NCT05369585
    completedphase_2_3

    Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes

    NCT02868177

    Clinical Trials (2)

    Showing 2 of 2 trials
    NCT05369585Not Applicable

    Mode of Action (MoA) Study of TOTUM-63 in Individuals at Increased Cardio-metabolic Risk

    Completed
    NCT02868177Phase 2/3

    Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes

    Completed

    All 2 trials loaded

    Drug Details

    Intervention Type
    Dietary supplement
    Total Trials
    2